Dan Gibson

23PUBLICATIONS
55CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesCharacterisation of biological macromoleculesNonlinear optics and spectroscopyMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 04, 2026
A Cisplatin-Based Prodrug Inhibits Nucleotide Excision Repair Independently of Chromatin Accessibility to Overcome Resistance.

|Jan 15, 2026
A New Class of Multitargeting Pt<sup>IV</sup> Anticancer Agents: Prodrugs That Release Pt<sup>II</sup> Drugs and Bioactive Moieties Tethered to Pt<sup>IV</sup> via a Tertiary Amine.

Moumita Maji, Michele De Franco, Sourav Acharya

|Nov 10, 2025
Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models.

Sofia Sharkawy, Sourav Acharya, Hana Kostrhunová

|Sep 23, 2025
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.

Jia Xuan Kee, Jia Ning Nicolette Yau, Ram Pravin Kumar Muthuramalingam

|Jan 08, 2025
Multitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain.

Tomer Babu, Ram Pravin Kumar Muthuramalingam, Wei Heng Chng

|May 31, 2024
Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.

Lenka Markova, Moumita Maji, Hana Kostrhunova

Pageof 4

Frequent Collaborators

7 joint publications

Subhendu Karmakar

6 joint publications

Viktor Brabec

6 joint publications

Valentina Gandin

6 joint publications

Tomer Babu